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Abstract
As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and 
Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza 
in Melbourne received a record total of 5866 human influenza positive samples during 2017. Viruses 
were analysed for their antigenic, genetic and antiviral susceptibility properties and were propagated 
in qualified cells and hens’ eggs for use as potential seasonal influenza vaccine virus candidates. In 
2017, influenza A(H3) viruses predominated over influenza A(H1)pdm09 and B viruses, accounting 
for a total of 54% of all viruses analysed. The majority of A(H1)pdm09, A(H3) and influenza B viruses 
analysed at the Centre were found to be antigenically similar to the respective WHO recommended 
vaccine strains for the Southern Hemisphere in 2017. However, phylogenetic analysis indicated that 
the majority of circulating A(H3) viruses had undergone genetic drift relative to the WHO recom-
mended vaccine strain for 2017. Of 3733 samples tested for susceptibility to the neuraminidase 
inhibitors oseltamivir and zanamivir, only two A(H1)pdm09 viruses and one A(H3) virus showed 
highly reduced inhibition by oseltamivir, while just one A(H1)pdm09 virus showed highly reduced 
inhibition by zanamivir.
Keywords: GISRS, influenza, vaccines, surveillance, laboratory, annual report, WHO
Introduction
The WHO Collaborating Centre for Reference 
and Research on Influenza in Melbourne (the 
Centre) is part of the World Health Organization 
Global Influenza Surveillance and Response 
System (WHO GISRS). GISRS is a worldwide 
network of laboratories that was established in 
1952 to monitor changes in influenza viruses cir-
culating in the human population, with the aim 
of reducing its impact through the use of vaccines 
and antiviral drugs.1,2 The Centre in Melbourne 
is one of five such Collaborating Centres (the 
others being in Atlanta, Beijing, London and 
Tokyo) that monitor the antigenic and genetic 
changes in circulating human influenza viruses, 
and makes bi-annual recommendations on 
which influenza strains should be included in 
the influenza vaccine for the upcoming influ-
enza season in either the northern or southern 
hemisphere. This report summarises the results 
of virological surveillance activities undertaken 
at the Centre in Melbourne during 2017.
Two types of influenza cause significant disease 
in humans: types A and B. Influenza A viruses 
are further classified into subtypes, based on 
their haemagglutinin (HA) and neuraminidase 
(NA) surface proteins. Globally, there are cur-
rently two influenza A subtypes circulating in 
the human population: A(H1N1)pdm09 and 
A(H3N2). Influenza B viruses are not clas-
sified into subtypes; however, there are two 
distinct co-circulating lineages of influenza B 
viruses - B/Victoria/2/87 (B/Victoria lineage) 
and B/Yamagata/16/88 (B/Yamagata lineage). 
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In addition, each year influenza C viruses are 
detected from humans, but these viruses do not 
cause severe disease and are not a major focus of 
influenza surveillance.
Methods
Virus isolation
All A(H1)pdm09 and all influenza B viral iso-
lates received at the Centre were re-passaged 
in cell culture (Madin-Darby Canine Kidney 
(MDCK) cells), whilst all A(H3) viral isolates 
were re-passaged in MDCK-SIAT1 cells.3 Virus 
isolation in cell culture was also attempted 
from a selection of original clinical specimens 
received. A smaller subset of influenza positive 
original clinical samples was directly inoculated 
into eggs and a qualified cell line as potential 
candidate vaccine viruses.
Antigenic analysis
The antigenic properties of influenza viral 
isolates were analysed using the haemagglu-
tination inhibition (HI) assay as previously 
described.4 The majority of the HI assays were 
performed using the TECAN Freedom EVO200 
robot platform which incorporates a camera 
(SciRobotics, Kfar Saba, Israel) and imaging 
software (FluHema™) for automated analysis. 
In HI assays, viruses were tested for their abil-
ity to agglutinate turkey (A(H1N1)pdm09 and 
B viruses) or guinea pig (A(H3N2) viruses) red 
blood cells (RBC) in the presence of ferret anti-
sera previously raised against several reference 
viruses. Isolates were identified as antigenically 
similar to the reference strain if the test samples 
had a titre that was no more than 4-fold different 
from the titre of the homologous reference strain. 
During 2017, results were reported with refer-
ence to the A/Michigan/45/2009 (H1N1pdm09)-
like, A/Hong Kong/4801/2014 (H3N2)-like, B/
Brisbane/60/2008-like (Victoria lineage), and 
B/Phuket/3073/2013-like (Yamagata lineage) 
viruses that were recommended for inclusion 
in the southern hemisphere 2017 influenza vac-
cine. In recent years (including 2017), HI assays 
involving A(H3) viruses have been performed 
in the presence of oseltamivir carboxylate (OC) 
in order to reduce non-specific binding of the 
NA protein.5 The addition of OC reduces the 
number of influenza virus isolates that can 
be tested by HI as around 40% of viruses lose 
the ability to bind RBC. Hence other methods 
such as the Focus Reduction Assay (FRA) or 
Microneutralisation assays (MNT) have been 
employed to test a subset of these viruses.
Genetic analysis
For influenza-positive samples that failed to 
grow in MDCK cells, real-time RT-PCR was 
performed to determine the influenza type/
subtype/lineage using kits obtained through 
the International Reagent Resource,i Influenza 
Division, WHO Collaborating Centre for 
Surveillance, Epidemiology and Control of 
Influenza, Centers for Disease Control and 
Prevention (CDC), Atlanta, GA, USA. The CDC 
Influenza Virus Real-Time RT-PCR kits were 
used to identify influenza A, influenza B, A(H1)
pdm09, A(H3), B/Yamagata and B/Victoria 
viruses.
A substantial subset of all influenza viruses ana-
lysed at the Centre underwent genetic analysis by 
sequencing of viral RNA genes, usually HA and 
NA genes as well as the matrix gene for influ-
enza A viruses and non-structural protein gene 
(NS) for influenza B viruses. The full genomes 
(all eight gene segments) of a smaller subset of 
viruses were also sequenced.
For sequencing, RNA was extracted from iso-
lates or original clinical specimens using either 
a manual QIAGEN QIAamp Viral RNA kit or 
the automated QIAGEN QIAXtractor platform, 
followed by reverse transcription PCR using the 
BIOLINE MyTaq one step reverse transcription 
PCR kit according to the manufacturer’s recom-
mendations, with gene specific primers (primer 
sequences available on request). Conventional 
Sanger sequencing was carried out on PCR 
products using an Applied Biosystems 3500XL 
Genetic Analyzer (Applied Biosystems, Foster 
i https://www.internationalreagentresource.org/ 
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City, CA, USA). Sequence assembly was per-
formed using the SeqMan Pro module of 
DNASTAR Lasergene version 13 software 
(DNASTAR, Madison, WI, USA). Next genera-
tion sequencing (NGS) was also performed on a 
selection of viruses using an Applied Biosystems 
Ion Torrent™ Personal Genome Machine™ 
(PGM) System according to the manufacturer’s 
recommendations. These sequences were ana-
lysed using a proprietary pipeline, FluLINE.6 
Phylogenetic analysis was performed using 
Geneious 9.0.4 (Biomatters Ltd, Auckland, New 
Zealand) and FigTree v1.3.1 software.
Antiviral drug resistance testing
Circulating viruses were tested for their 
sensitivity to the currently used neurami-
nidase inhibitors oseltamivir (Tamiflu) and 
zanamivir (Relenza). The neuraminidase 
inhibition (NAI) assay used was a functional 
fluorescence-based assay using the substrate 
20-(4-methylumbelliferyl)-a-D-N-acetylneu-
raminic acid (MUNANA), in which the suscep-
tibility of test viruses to the antiviral drugs was 
measured in terms of the drug concentration 
needed to reduce the neuraminidase enzymatic 
activity by 50% (IC50), and compared to values 
obtained with sensitive reference viruses of 
the same subtype or lineage. NAI assays were 
performed as previously described7 with the 
incorporation of a robotic platform by TECAN 
EVO200 and Infinite 200Pro for liquid handling 
and plate reading (Tecan Australia). For the pur-
poses of reporting, reduced inhibition of influ-
enza A viruses has been defined by WHO as a 
10–99 fold increase in IC50, while highly reduced 
inhibition is defined as a ≥ 100-fold increase in 
IC50 in an NAI assay. For influenza B viruses, 
these figures have been defined as 5–49 fold 
and ≥50 fold increases, respectively. However, 
it should be noted that the relationship between 
the IC50 value and the clinical effectiveness of a 
neuraminidase inhibitor is not well understood 
and a reduction in inhibition may not be clini-
cally significant.
Viruses found to have highly reduced inhibition 
by either oseltamivir or zanamivir underwent 
genetic analysis using pyrosequencing, Sanger 
sequencing or NGS to determine the presence of 
amino acid substitutions in the neuraminidase 
protein that were associated with the reduction of 
inhibition by NAIs. For example, a change from 
histidine to tyrosine at position 275 (H275Y) 
of the neuraminidase protein of A(H1N1)
pdm09 viruses is known to reduce inhibition by 
oseltamivir, as does the H273Y neuraminidase 
mutation in B viruses.8 Pyrosequencing was 
also performed on original clinical specimens 
of selected viruses which may have contained a 
known mutation such as H275Y but for which 
no isolate was available. Pyrosequencing was 
performed as previously described9 using 
the MyTaq One-Step RT-PCR Kit (QIAGEN, 
Hilden, Germany) for virus amplification, with 
pyrosequencing reactions performed using 
the PyroMark instrument (QIAGEN, Hilden, 
Germany).
Candidate vaccine strains
The viruses used to produce human influenza 
vaccines are required to be isolated and pas-
saged in embryonated hens’ eggs or qualified cell 
lines.10–12 The Centre undertook primary isola-
tion of selected viruses from clinical samples 
directly into eggs, using previously described 
methods,13 with the following modifications. 
First, the viruses were inoculated only into the 
amniotic cavity. Once growth was established, 
the isolates were passaged in the allantoic cav-
ity. Egg incubation conditions differed slightly 
with A(H1)pdm09 and A(H3) viruses incubated 
at 35oC for three days, and influenza B viruses 
incubated at 33oC for three days. In addition, 
selected clinical samples were inoculated into 
the qualified cell line MDCK 33016PF and incu-
bated at 35oC for 3 days and viral growth was 
monitored by haemagglutination of turkey or 
guinea pig RBC. These isolates were then ana-
lysed by HI assay, real time RT-PCR and genetic 
sequencing using the methods described above.
Results
During 2017, the Centre received 5866 clini-
cal specimens and/or virus isolates from 41 
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laboratories in 14 countries (Figure 1). As in 
previous years, most samples were submitted by 
laboratories in the Asia-Pacific region, including 
Australian laboratories14 and were received dur-
ing the Southern Hemisphere influenza season 
(June-October). Figure 2 shows the weekly tem-
poral distribution of samples sent to the Centre by 
type/subtype and lineage. During 2017, influenza 
A(H3) was the predominant circulating strain, 
although a significant proportion of influenza B 
viruses co-circulated. For samples received from 
Australia and where lineage could be confirmed, 
B/Yamagata viruses predominated extensively 
over B/Victoria viruses. Overall, isolation was 
attempted for 5167 (88%) of the samples received 
and yielded 3761 isolates (overall isolation rate 
of 73%). Of the viruses for which type and sub-
type could be confirmed, isolation rates of 86% 
(581/675) for A(H1)pdm09, 84% (1984/2360) 
for A(H3) and 84% (1196/1424) for influenza B 
were obtained. However, amongst these viruses, 
39% (781/1984 isolated) of A(H3) isolates did 
not reach sufficient titres for antigenic analysis. 
A total of 2744 viral isolates were successfully 
characterised by HI assay in comparison to the 
2017 vaccine-like reference viruses (Table 1). In 
addition, 884 samples were characterised by real-
time RT-PCR to determine their type/subtype or 
lineage. Sanger sequencing and NGS techniques 
were used to sequence the haemagglutinin genes 
of 1965 viruses. The full genomes of 109 viruses 
were sequenced using either Sanger sequencing 
or NGS. Of the samples for which results could 
be obtained via antigenic or genetic analysis 
(n=4663), influenza A(H3) viruses predomi-
nated, comprising 54% (2514/4663) of viruses 
analysed. The remaining portion of viruses were 
mostly influenza B viruses (32% of viruses ana-
lysed; comprising 5% B/Victoria (209/4663) and 
27% B/Yamagata (1274/4663)), followed by 14% 
A(H1)pdm09 (666/4663 of viruses analysed).
A(H1N1)pdm09
Of the 578 A(H1)pdm09 isolates analysed by HI 
assay using ferret antisera in 2017, the majority 
(99%) were antigenically similar to the vaccine 
reference strain A/Michigan/45/2015 (Table 1).
Sequencing and phylogenetic analysis of HA 
genes from 175 viruses showed that A(H1)pdm09 
viruses sent to the Centre during 2017 fell mainly 
into the 6B.1 subclade with a smaller number of 
viruses in subclade 6B.2 (Figure 3). No antigenic 
differences were detectable between viruses from 
the 6B, 6B.1 or 6B.2 genetic clades in HI assays 
using ferret antisera and the majority of viruses 
reacted in a similar manner to the reference and 
2017 vaccine virus A/Michigan/45/2015.
Figure 1. Geographic spread of influenza laboratories sending viruses to the Centre during 2017.
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Figure 2. Number of samples received at the Centre by week of sample collection, 2017.
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Five viruses were inoculated into eggs for isola-
tion of candidate vaccine strains. Of these, four 
(80%) were successfully isolated, all of which fell 
into subclade 6B.1.
Of 578 A(H1)pdm09 viruses tested, two viruses 
exhibited highly reduced inhibition by oseltami-
vir. Both of these viruses—one from Singapore 
and one from Sydney—were confirmed to con-
tain the H275Y mutation in their NA genes, a 
known mutation that is associated with reduced 
inhibition of oseltamivir. Another virus from 
Queensland had highly reduced inhibition by 
zanamivir and contained a Q136R mutation 
in its NA gene. Pyrosequencing of the original 
specimens of an additional four viruses from 
Perth revealed that they all contained the H275Y 
mutation in their NA gene.
A(H3N2)
Antigenic analysis of 974 A(H3) subtype isolates 
using the HI assay showed that 20.5% were low 
reactors to the ferret antisera prepared against 
the cell-propagated reference strain A/Hong 
Kong/4801/2014 (Table 1). However, 40.5% of 
viruses were low reactors to the ferret antisera 
prepared against the egg-propagated strain A/
Hong Kong/4801/2014 (data not shown). An 
additional 781 A(H3) viruses were inoculated 
and isolated by cell culture but did not reach 
sufficient titres for antigenic analysis, whilst a 
further 229 were successfully isolated but did not 
reach sufficient titres when tested by HI assay in 
the presence of oseltamivir carboxylate.
The HA genes of 1582 A(H3) viruses were 
sequenced. Phylogenetic analysis indicated that 
the majority of circulating viruses fell into sub-
clade 3C.2a1 based on their HA genes, which is 
genetically different to the 2017 vaccine strain A/
Hong Kong/4801/2014 (clade 3C.2a) (Figure 4). 
A smaller proportion of A(H3) viruses fell into 
the 3C.2a2, 3C.2a3 and 3C.2a4 clades.
In total 80 viruses were inoculated into eggs, of 
which 30 (38%) grew successfully. These consisted 
of 17 viruses from clade 3C.2a, which included 
seven from subclade 3C.2a1. Additionally, three 
viruses were isolated from subclade 3C.2a2, 
three from 3C.2a3, five from 3C.2a4 and two 
from 3C.3a.
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A/Perth/339/2017 nov
A/Sri Lanka/40/2017 mar
A/Sydney/1054/2017 aug
A/Sydney/709/2017 sep
A/South Australia/10/2017 jan
A/Victoria/671/2017 aug
A/Wellington/3/2017 may
A/Cambodia/B0629535/2017 jun
A/Wellington/41/2017 jul
A/Newcastle/67/2017e jun
A/Dunedin/2/2017 jun
A/Victoria/55/2017 jul
A/Perth/85/2017 jun 
A/Sydney/1078/2017 aug
A/Victoria/12/2017 jun
A/Tasmania/8/2017 jan
A/Sydney/1077/2017 aug
A/Brisbane/81/2017e jun
* A/VICTORIA/503/2016
A/Dunedin/3/2017 aug
A/Victoria/238/2017 oct
# A/MICHIGAN/45/2015e
A/Cambodia/B0620538/2017 jun
A/Brisbane/6/2017 jan
A/South Africa/R05836/2017 jul
A/Newcastle/71/2017 jul
A/Townsville/9/2017 jul 
A/Tasmania/1005/2017 aug
A/Sydney/1001/2017 apr
A/Surat Thani/37/2017 apr
A/Victoria/226/2017 oct
A/Victoria/897/2017 oct
* A/DARWIN/56/2013
A/Victoria/616/2017 jul
A/Brisbane/31/2017 mar
* A/SOUTH AUSTRALIA/22/2015e
A/Brisbane/71/2017 may
A/Cambodia/b0629529/2017 jul
A/Brisbane/1030/2017 aug
A/South Australia/16/2017 jan
A/Perth/10/2017 jan
A/Wellington 6/2017 may
A/Cambodia/B0711507/2017 jul
A/Canterbury/7/2017 may
A/Victoria/2110/2017 aug
A/Newcastle/83/2017 jun
A/Sri Lanka/61/2017 jul
A/South Australia/196/2017 jul
A/Sri Lanka/82/2017 aug
A/Sydney/153/2017 jul
A/Brisbane/1005/2017 jul
A/Perth/334/2017 oct
A/Newcastle/194/2017 aug
A/South Australia/1027/2017 aug
* A/SINGAPORE/GP1908/2015e
A/Victoria/2073/2017 aug
A/Cambodia/b0629530/2017 jul
* A/CHRISTCHURCH/16/2010e
A/Canberra/1002/2017 aug
A/Tasmania/56/2017 aug
A/Brisbane/70/2017e may
* A/FIJI/3/2016e
A/Brisbane/183/2017 oct
A/South Africa/R07191/2017 jul
A/Brisbane/117/2017 jul
* A/PERTH/103/2015
A/Victoria/2058/2017 aug
* A/TASMANIA/24/2014e
A/Christchurch/519/2017 sep
A/Auckland/517/2017 aug
A/Victoria/570/2017 jul
A/Victoria/644/2017 aug
* A/BRISBANE37/2017 apr
A/Canberra/29/2017 jul
A/South Australia/167/2017 jul
A/Nakhonphanom/34/2017 may
A/Canberra/50/2017 aug
A/Townsville/11/2017 jul
* A/CALIFORNIA/07/2009e
A/Brisbane/104/2017 jul
A/Brisbane/191/2017 oct
A/Townsville/8/2017 jun
A/Sydney/703/2017 sep
A/Cambodia/B0710501/2017 jun
A/Philippines/5/2017 jun
A/Perth/88/2017 jun
A/Victoria/733/2017 sep
A/Brisbane/17/2017 jan
A/Sri Lanka/13/2017 apr
A/Canberra/42/2017 aug
A/Canterbury/13/2017 jun
A/Perth/119/2017 jul
A/Canberra/9/2017 apr
A/Canterbury/3/2017 mar
A/Perth/100/2017 jul
A/South Australia/1025/2017 aug
A/Newcastle/86/2017e jun  
A/Malaysia/RP0362/2017
A/South Australia/138/2017 jun
A/Victoria/536/2017 jul
A/South Australia/262/2017 oct
S185T
S451N 
D97N, K163Q, A256T, K283E, E499K
V152T, V173I, E491G, D501E
S84N, S162N(+), I216T
S74R
I295V
H273Q
R45K
K308R
S164T
A215G
I404L, I418V
S534G
D35G
V47M
H399Q, T483S
4 7
6B.2
6B.1
6B
Figure 3. Phylogenetic tree of haemagglutinin 
genes of A(H1)pdm09 viruses received by the 
Centre during 2017.
Legend:
#  2017 SOUTHERN HEMISPHERE VACCINE STRAIN
*  REFERENCE VIRUS
e:  egg isolate
Scale bar represents 0.4% nucleotide sequence difference 
between viruses
Amino acid changes relative to the outgroup sequence (A/
CALIFORNIA/07/2009e) are shown
(+/-) indicates gain/loss of a potential glycosylation site
] Braces indicate clades
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0.004
A/Christchurch/515/2017 oct
A/Newcastle/78/2017 jun
A/Wellington/35/2017 jul
* A/CHRISTCHURCH/5/2016 jun
A/Victoria/233/2017 sep
A/Darwin/1005/2017 mar
A/Perth/57/2017 mar
A/Perth/64/2017 apr
A/Tasmania/21/2017 jul
A/Tasmania/76/2017 oct
A/Perth/330/2017 oct
A/Canberra/6/2017 apr
A/South Australia/111/2017 may
A/South Australia/41/2017 feb
A/Kalamata/540/2017e
A/Brisbane/1096/2017 oct
A/Brisbane/32/2017e mar
A/Newcastle/36/2017e apr
A/South Australia/4/2017 jan
A/Victoria/221/2017 sep
* A/SYDNEY/142/2016e jun
A/Victoria/1008/2017 jul
A/Victoria/60/2017 aug
A/Perth/333/2017 oct
A/Sydney/1050/2017 aug
A/Christchurch/504/2017 jun
A/Sri Lanka/72/2017 jul
* A/ALASKA/232/2015e
A/New Caledonia/3/2017 aug
A/Perth/77/2017 may
A/Wellington/1/2017 may
A/Victoria/887/2017 oct
A/Sydney/220/2017 oct
A/Fiji/50/2017 mar
A/Victoria/893/2017 oct
A/South Africa/R05656/2017 jul
A/Bay of Plenty/2/2017 apr
A/Fiji/72/2017 sep
A/South Australia/90/2017e may
A/Sri Lanka/5/2017 jan
A/Sydney/81/2017 apr
A/Darwin/1001/2017 jan
A/Sydney/52/2017e mar
A/Canterbury/15/2017 jul
A/Victoria/655/2017 aug
A/South Australia/79/2017 apr
A/Brisbane/185/2017 oct
A/Victoria/896/2017 oct
A/Fiji/69/2017 jul
A/South Africa/R06642/2017 jul
A/Sri Lanka/56/2017 jul
A/Newcastle/35/2017e mar
A/Newcastle/45/2017 mar
A/Victoria/186/2017 sep
A/Sri Lanka/3/2017 jan
A/Sydney/147/2017 may
A/Greece/4/2017e jan
A/Brisbane/1017/2017 aug
A/Brisbane/4/2017e jan
A/Sydney/1079/2017 aug
A/Brisbane/2/2017 jan
A/South Africa/R06243/2017 jul
A/Victoria/192/2017 sep
A/South Auckland/43/2017 apr
A/Victoria/196/2017 sep
A/Victoria/2035/2017 jul
* A/SINGAPORE/INFIMH-16-0019/2016e
A/Canberra/25/2017 jul
A/Washington/16/2017e jan
* A/MICHIGAN/15/2014
A/Canberra/41/2017 aug
A/South Australia/26/2017 feb
* A/NEWCASTLE/30/2016
A/Newcastle/196/2017 aug
A/Tasmania/75/2017 oct
A/Brisbane/1028/2017 aug
A/South Australia/19/2017 jan
A/Perth/331/2017 oct
A/Victoria/888/2017 oct
A/Victoria/742/2017 sep
* crickA/SWITZERLAND/9715293/2013e
* A/NEWCASTLE/22/2014e
* A/BRISBANE/296/2016 nov
# A/HONG KONG/4801/2014e
A/Victoria/740/2017 sep
A/Sydney/51/2017 mar
A/Townsville/5/2017 mar
A/Perth/322/2017 oct
A/South Australia/22/2017 jan
A/South Australia/13/2017 jan
A/South Auckland/16/2017 mar
A/Brisbane/1098/2017 oct
A/Brisbane/187/2017 oct
A/Hong Kong/2277/2017e
A/Victoria/534/2017 jul
A/Wellington/44/2017 jul
A/SouthAustralia/261/2017 oct
A/Papua New Guinea/19/2017 mar
3C.3a
3C.3b
3C.3
3C.2a1
3C.2a4
3C.2a2
3c.2a3
3C.2a
K92R, Q197K
S198P, S312N
L3I
D489N
S91N, N144K(-), F193S
R326K
R140I
V186G I3L, N489D
A128T(+), S138A
S159Y, Q311H
K160T(+)
N31S, D53N
N144R(-), N171K
I192T, Q197H
A304T
S442A
N144K(-)
R261Q
T135K(-)
R150K
N121K
N171K
R261Q, I406V
G484E
K121N, Q261R
N121K
K92R
H311Q
E62G
R142G
T135K(-)
K83R, R261Q
T135K(-)
G479E N122D(-)
N122D(-), S262N
K121N, T131K
R142K, R261Q
G142R
R142G, G479E
Figure 4. Phylogenetic tree of haemagglutinin 
genes of A(H3) viruses received by the Centre 
during 2017.
Legend:
# 2017 SOUTHERN HEMISPHERE VACCINE STRAIN
* REFERENCE VIRUS
e: egg isolate
Scale bar represents 0.4% nucleotide sequence difference 
between viruses
Amino acid changes relative to the outgroup sequence (crickA/
SWITZERLAND/9715293/2013e) are shown
(+/-) indicates gain/loss of a potential glycosylation site
] Braces indicate clades
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Of the 1960 A(H3) viruses tested by NAI assay, 
only one virus from Sydney showed highly 
reduced inhibition by oseltamivir and was found 
to contain a R292K mutation in its NA gene.
Influenza B
Amongst influenza B viruses received at the 
Centre during 2017, B/Yamagata lineage viruses 
were predominant over B/Victoria lineage 
viruses (Figure 2). A total of 1192 influenza 
B viruses were characterised by HI assay and 
almost all were antigenically similar to the B/
Brisbane/60/2008-like and B/Phuket/3073/2013-
like vaccine viruses for the B/Victoria and B/
Yamagata lineages respectively (Table 1).
Sequencing was performed on HA genes 
from 208 B viruses, with the majority being 
B/Yamagata viruses. All of the viruses of B/
Victoria lineage were genetically similar to the 
B/Brisbane/60/2008 reference virus (Figure 5). 
B/Victoria viruses bearing a two amino acid 
deletion in the HA protein at positions 162-163 
have been increasing in frequency in many 
countries,15 however, only one such virus was 
detected (B/Victoria/3/2017) amongst viruses 
received at the Centre. The majority of B/
Yamagata lineage viruses belonged to Clade 3, 
which is the same genetic clade as the 2017 vac-
cine virus B/Phuket/3073/2013 (Figure 6).
Egg isolation was attempted for five B/Victoria 
and six B/Yamagata viruses, resulting in the suc-
cessful isolation of four (80%) B/Victoria viruses 
and six (100%) B/Yamagata viruses. At least one 
representative from the major clades of both B 
lineages was amongst the successful egg isolates. 
Of 200 B/Victoria and 995 B/Yamagata viruses 
tested, none displayed highly reduced inhibition 
by oseltamivir or zanamivir.
Discussion
In 2017 the majority of samples received at the 
Centre were from Australia (76%), which was 
similar to previous years.14,16,17 Furthermore, 
during 2017, the Centre received the largest 
number of samples since the pandemic in 2009. 
This correlated with record notifications of 
laboratory-confirmed influenza during the 2017 
Australian influenza season (over 250,000 cases), 
and was the highest recorded influenza activity 
since influenza became a notifiable disease in 
2001, surpassing notifications both during the 
2009 pandemic and the previous annual high 
in 2015.18 The geographical spread of influenza 
around the country in 2017 was uneven, as 
Western Australia experienced lower levels of 
activity compared to elevated levels in southern 
and eastern jurisdictions.19 The large increase 
in reported influenza activity during 2017 has 
been partly attributed to the early onset and 
prolonged length of the influenza season as well 
as increased use of diagnostic testing in clinical 
settings. However low vaccine effectiveness, in 
particular for the A(H3) subtype, has also been 
identified as a likely contributor to the high 
influenza activity in 2017.19,20 For the entire sea-
son, influenza A(H3) was the predominant cir-
culating strain, followed by influenza B viruses, 
of which B/Yamagata viruses predominated 
over B/Victoria viruses. This pattern was also 
reflected in the relative proportions of samples 
received at the Centre during 2017.
Elderly populations are disproportionately 
affected in years when A(H3) viruses are pre-
dominant.21 In 2017 this was consistent with the 
fact that notification rates were highest for adults 
aged 80 years and older compared to younger 
age groups (2,974 notifications per 100,000 pop-
ulation for adults ≥85 years, 1,894 notifications 
per 100,000 population for adults aged 80–84 
years).18 This is unsurprising given the predomi-
nance of A(H3) viruses during the season and 
the increase in influenza notifications and sam-
ples received by the Centre. A secondary smaller 
peak in young children aged 5 to 9 years (1,696 
notifications per 100,000 population) has been 
largely attributed to influenza B.18
Due to this demographic, an increased number 
of deaths associated with influenza and pneu-
monia were reported in 2017, with 745 influenza 
associated deaths notified to the NNDSS by 
the end of November 2017. The median age of 
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Figure 5. Phylogenetic tree of haemagglutinin genes of B/Victoria viruses received by the Centre 
during 2017.
Legend:
# 2017 SOUTHERN HEMISPHERE VACCINE STRAIN
* REFERENCE VIRUS
e: egg isolate
Scale bar represents 0.2% nucleotide sequence difference 
between viruses
Amino acid changes relative to the outgroup sequence (B/
SYDNEY/508/2010e) are shown
V1A - 3 DEL and V1A - 2 DEL indicate amino acid deletions at the 
positions indicated
] Braces indicate clades
0.002
B/Victoria/877/2017e oct
* B/DARWIN/40/2012
B/Victoria/533/2017 aug
B/South Australia/7/2017 feb
cdcB/Alabama/02/2017 jan del 162/163
B/Victoria/3/2017 jun del 162/163
cdcB/Tanzania/4351/2017 mar
B/Brisbane/1012/2017 aug
B/Iowa/14/2017e mar del 162/163
cdcB/Ecuador/2934/2017 mar
B/Norway/2409/2017e del 162/163
B/Brisbane/3/2017 jan
B/Tasmania/1000/2017 mar
cnicB/Sichuan Qingyang/11794/2017 nov
* cdcB/TEXAS/02/2013e
B/Brisbane/9/2017 may
cdcB/Brazil/4558/2017 may
B/Sydney/8/2017 feb
B/Lakes/1/2017 jan
B/NakhonSiThammarat/8/2017 feb
cdcB/Wisconsin/76/2017 dec del 162/163
B/South Australia/63/2017 jun 
ispB/Santiago/30900/2017 apr
cdcB/Colorado/06/2017 feb del 162/163
* B/BRISBANE/18/2013e
ispcB/Rancagua/90687/2017 nov
B/Cambodia/B0629525/2017 may
cdcB/Peru/0017/2017 jun
B/Brisbane/14/2017 jun
B/Perth/11/2017 jul
B/Newcastle/4/2017 feb
B/Victoria/513/2017 jul
B/Victoria/859/2017e oct
B/Darwin/108/2017 oct
* B/BRISBANE/46/2015e
cdcB/Hawaii/67/2017 nov
# B/BRISBANE/60/2008e  
* B/VICTORIA/502/2015e
* B/TOWNSVILLE/8/2016
B/Hong Kong/269/2017e del 162-164
B/South Australia/20/2017 apr
cdcB/Suriname/2085/2017 may del 162/163
ipB/Centre/1582/2017 nov
* B/SYDNEY/508/2010e
B/Wellington/20/2107 jun
B/Darwin/109/2017e oct
B/Cambodia/FSS34628/2017 feb
cdcB/Analavory/2825/2017 jun
crickB/Dakar/09/2017 apr
cdcB/California/60/2017 nov
B/Perth/62/2017 nov
crickB/Tamasina/1433/2017 apr
B/Sydney/4/2017 jan
* B/SOUTH AUSTRALIA/81/2012e nov
B/Sydney/32/2017 jun
cdcB/Rio Grande Do Norte/146306-IEC/2017 mar
B/Victoria/531/2017 aug
cdcB/Nebraska/04/2017 feb del 162/163
crickB/Nosy Be/1638/2017 apr
N129D
I117V
P58L
V146I
V146I
D526E
D129G
I180V
R498K
I261L
V87A, I175V
V1A - 
3 DEL
V1A - 
2 DEL
V1B
V1A
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Figure 6. Phylogenetic tree of haemagglutinin genes of B/Yamagata viruses received by the Centre 
during 2017.
Legend:
# 2017 SOUTHERN HEMISPHERE VACCINE STRAIN
* REFERENCE VIRUS
e: egg isolate
Scale bar represents 0.5% nucleotide sequence difference 
between viruses
Amino acid changes relative to the outgroup sequence (cdcB/
MASSACHUSETTS/02/2012e mar) are shown
(+/-) indicates gain/loss of a potential glycosylation site
] Braces indicate clades
0.005
B/Brisbane/25/2017 jul
B/Victoria/2018/2017 jul
B/Victoria/536/2017 aug
* B/BRISBANE/9/2014e mar
B/Victoria/501/2017 jun
B/South Africa/R07025/17 jul
B/New Caledonia/10/2017 feb
B/Sydney/1021/2017 jul
B/Newastle/8/2017 jul
B/Sydney/26/2017 may
B/South Auckland/31/2017 apr
B/Victoria/547/2017e aug
B/South Australia/1006/2017 aug
B/Sydney/1054/2017 aug
B/Christchurch/505/2017 jun
B/Fiji/34/2017 oct
B/Wellington/22/2017 jun
B/Wellington/14/2017 may
B/Fiji/5/2017 mar
B/Darwin/24/2017 aug
B/Victoria/580/2017 sep
B/Dunedin/1/2017 jun
B/Surat Thani/14/2017 mar
B/Sukhothai/18/2017 mar
* B/SYDNEY/39/2014e dec
* B/MALAYSIA/412/2012e
# B/PHUKET/3073/2013e nov
B/South Australia/4/2017 jan
B/Darwin/3/2017 jan
B/South Australia/67/2017 jul
B/Victoria/10/2017 jul
B/Victoria/540/2017e aug
* cdcB/MASSACHUSETTS/02/2012e mar
B/South Africa/R07361/2017 jul
B/Wellington/10/2017 may
B/Papua New Guinea/1/2017 Mar
B/Brisbane/11/2017 jun
B/Wellington/17/2017 jun
B/Victoria/2/2017 may
B/Nonthaburi/30/2017 apr
B/Christchurch/507/2017 oct
B/Wellington/18/2017 may
B/Victoria/587/2017 sep
B/Brisbane/29/2017 aug
B/Wellington/40/2017 jul
* cdcB/HUBEI/WUJIAGANG/158/2009e
B/Wellington/83/2017 sep
B/Philippines/1/2017 mar
B/Victoria/592/2017 sep
B/Waikato/3/2017 may
B/Victoria/2015/2017 jul
B/Brisbane/1037/2017 sep
B/Fiji/12/2017 apr
B/Brisbane/7/2017 mar
B/Tasmania/1019/2017 oct
B/Victoria/526/2017 jul
B/Brisbane/13/2017 jun
B/Perth/4/2017 apr
B/Victoria/590/2017 sep
B/Newcastle/11/2017 jun
B/Darwin/99/2017 nov
B/Townsville/1/2017 feb
B/South Australia/32/2017 may
B/South Auckland/14/2017 may
B/Victoria/541/2017e aug
* cdcB/WISCONSIN/01/2010e
B/Perth/61/2017 nov
B/Tasmania/30/2017 aug
B/Tasmania/16/2017 jul
B/Sydney/7/2017 mar
B/Brisbane/8/2017 apr
B/South Auckland/22/2017 jun
B/Canberra/12/2017 jul
B/Victoria/109/207 oct
B/Newcastle/23/2017 aug
B/Sydney/11/2017 apr
B/Victoria/867/2017 oct
B/Brisbane/28/2017 jul
* B/SYDNEY/10/2016 feb
B/Christchurch/509/2017 oct
B/Tauranga/1/2017 may
B/Tasmania/27/2017 jun
B/Victoria/570/2017e sep
B/Darwin/1/2017 jan
B/Brisbane/2/2017 jan
B/Nonthaburi/109/2017 may
B/South Auckland/5/2017 mar
B/Sydney/1014/2017 jul
B/Darwin/12/2017 mar
B/Darwin/102/2017 oct
B/Canterbury/5/2017 apr
S150I, N166Y, A182T, G230D
N203S
N116K, K299E, E313K
L173Q, M252V
D164N
Q122K
D233N(+)
T76I
Y2
Y3
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patients who died was 86 years (range 3 to 107 
years),19 with the majority of deaths being attrib-
uted to influenza A.22
The extended duration of elevated influenza 
activity observed during the 2017 Australian 
influenza season and dominance of A(H3) 
viruses is consistent with low interim vaccine 
effectiveness (VE) estimates, particularly for 
the A(H3) subtype.23 The interim overall VE 
for 2017 was 33% (95% CI: 17 to 46%) with the 
lowest VE estimated for the A(H3) subtype 
(VE 10%, 95% CI: -16 to 31). Interim northern 
hemisphere VE estimates for the 2017–2018 sea-
son, which contained the same A(H3) vaccine 
strain component (A/Hong Kong/4801/2014) as 
the southern hemisphere in 2017, also reflected 
markedly lower VE estimates for A(H3) com-
pared to A(H1)pdm09 and influenza B.24–26
HI assays performed at the Centre showed that 
approximately 80% of A(H3) viruses tested were 
antigenically similar to the cell-propagated 
reference strain A/Hong Kong/4801/2014. 
However, almost half of the viruses analysed at 
the Centre were low reactors to the egg-derived 
A/Hong Kong/4801/2014 reference strain 
(data not shown). Adaptive changes acquired 
by A(H3) candidate viruses in their HA gene 
during propagation in eggs may alter their 
antigenicity and consequently produce lower 
VE. While every effort is made to obtain A(H3) 
egg isolates which retain the antigenic charac-
teristics of their cell-derived counterparts, the 
A(H3) component included in vaccines in recent 
years have been affected by such adaptations.27,28 
Interim VE estimates reported by the United 
States Department of Defense (DoD) during the 
northern hemisphere 2017–2018 season indi-
cated a higher VE for A(H3) compared to VE 
calculated for civilian populations (27–52% VE 
for DoD populations versus 25% VE in civilian 
populations),29 although the age structure and 
health status of these populations, as well as the 
type of vaccines used, are likely to be different. 
The components for the northern hemisphere 
2017–2018 influenza vaccine were the same as 
those for the southern hemisphere 2017 vaccine. 
However, more than half of the vaccines admin-
istered by the US DoD contained an A(H3) 
component that was propagated in cell culture 
instead of eggs, and it is possible the higher VE 
in this population may be partly attributable to 
the inclusion of cell-based vaccine components 
that do not contain the same adaptations as 
egg-based vaccine components. Analysis of data 
from the United States Medicare program also 
indicated VE for preventing influenza-related 
hospital encounters and inpatient stays in indi-
viduals aged ≥ 65 years was higher for cell-based 
vaccine compared to egg-based vaccines.30 At 
this time only egg-based influenza vaccines are 
available in Australia and as such these adapta-
tions to egg-based components remain an ongo-
ing concern in vaccine production and for VE.
In addition, there are ongoing difficulties in 
the antigenic characterisation of A(H3) viruses. 
Evolutionary changes in this subtype continue to 
create challenges in detecting antigenic changes 
using the HI assay.5,31 A large number of A(H3) 
viruses isolated in MDCK-SIAT-1 cells cannot 
be assayed by HI in the presence of oseltamivir 
carboxylate. After taking into account viruses 
that had insufficient titre for antigenic analysis 
following cell culture, as well as viruses that had 
insufficient titres when tested by HI assay in the 
presence of oseltamivir carboxylate, overall only 
49% of all A(H3) viruses received by the Centre 
during 2017 and isolated in cell culture were suc-
cessfully analysed by the HI assay. The Centre 
has developed Microneutralisation assays and 
the Focus Reduction Assay to characterise the 
antigenicity of circulating A(H3) viruses that 
cannot be run in HI assays. At this time, how-
ever, such assays remain time- and labour-inten-
sive and complement rather than replace the HI 
assay. Genetic analysis has therefore become an 
increasingly important tool for detecting both 
minor and major changes in circulating A(H3) 
viruses.
Genetic data from the Centre indicated that 
many viruses in 2017 fell into clade 3C.2a1, 
a growing subclade of 3C.2a in which the 
2017 vaccine strain, A/Hong Kong/4801/2014 
sits. Although viruses in the subclade 3C.2a1 
remain antigenically similar to other viruses in 
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3C.2a, the genetic drift of 3C.2a1 viruses and/
or unwanted egg adaptations appear to have 
affected the effectiveness of the A(H3) vaccine 
component. Taken together, low VE estimates, 
genetic drift and poor HI reactivity resulted 
in the decision to change the H3 vaccine com-
ponent in the 2018 vaccine to A/Singapore/
INFIMH-16–0019/2016.32
The majority of circulating A(H1)pdm09 viruses 
were antigenically similar to the cell-derived 
A/Michigan/45/2015 reference strain in the 
vaccine. Genetic analysis showed that almost 
all of the A(H1)pdm09 viruses received by the 
Centre in 2017 fell into the same clade (6B.1) 
as A/Michigan/45/2015. Moderate interim VE 
estimates (50%, 95% CI: 8 to 24%) were reported 
for the A(H1)pdm09 component of the 2017 
Australian vaccine.23
Finally, antigenic and genetic data indicated that 
both influenza B lineage viruses analysed by 
the Centre were a good match with the recom-
mended vaccine strains, B/Brisbane/60/2008 
(Victoria lineage) and B/Phuket/3073/2013 
(Yamagata lineage). This was also reflected 
in moderate VE estimates for adults for the 
Australian 2017 influenza season (VE 57%, 95% 
CI: 22–62%).23
With the continual change and evolution in 
influenza viruses and the absence of an effec-
tive universal vaccine, there remains a need for 
ongoing influenza surveillance and considered 
decision-making around influenza vaccine 
updates. The work performed by the Centre in 
Melbourne is crucial to the efforts of the global 
surveillance community to ensure that viruses 
recommended for the influenza vaccine remain 
updated and as closely matched to the future 
circulating viruses as possible.
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